News | April 25, 2023
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Subscribe To Our Newsletter & Stay Updated
